GH Stock Forecast & Price Target

Guardant Health has demonstrated robust financial momentum, with a two-year revenue CAGR projected at +28% from 2023-2025, driven by continued demand in colorectal cancer, breast cancer, and new monitoring applications, alongside expansion of reimbursement coverage for its molecular residual disease commercial efforts. The company exceeded revenue expectations for its Shield test, prompting an upward revision of its annual revenue guidance to reflect approximately 31% year-over-year growth for 2025. Additionally, the strong performance of Reveal, which is the fastest-growing oncology test, and improved assumptions for long-term revenue growth and margins suggest a positive outlook for Guardant Health's financial trajectory.

Guardant Health's medium-term revenue guidance for its Shield product has been perceived as underwhelming, leading to concerns regarding future growth potential. The company reported a significant adjusted EBITDA loss of $45.5 million in the third quarter of 2025, raising red flags about its financial stability amidst ongoing operational costs. Furthermore, potential regulatory setbacks or lack of compelling data could hinder the company's expansion efforts outside the U.S., contributing to a cautious outlook on the stock.